BC
DRNA

Brookfield Corp’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Brookfield Corp’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,895
Closed -$481K – 679
2021
Q2 		$481K Buy
+12,895
New +$395K ﹤0.01% 505

Other funds holding DRNA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Brookfield Corp's DRNA Position: Q3 2021 in Review

Brookfield Corp sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 12,895 shares — an estimated $481K sold.

Brookfield Corp first reported a position in DRNA in Q2 2021 and held it in 1 quarter. The position peaked at $481K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Brookfield Corp reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Brookfield Corp sold 12,895 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $481K.
  • Brookfield Corp first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Brookfield Corp's Dicerna Pharmaceuticals, Inc. position peaked at $481K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Brookfield Corp's 13F filing for Q3 2021, filed 16 Nov 2021.